Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-AML: Low vs High Intensity Therapy in Relapsed/Refractory AML
NCT06713837Phase 3Recruiting
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Feb 2025
- Primary completion
- Jan 2028
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Event-Free Survival at 36 months. Started Feb 2025; status: recruiting.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06713837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713837.